key: cord-0937838-vqz6b7zy
authors: LaCourse, Sylvia M; John-Stewart, Grace; Adams Waldorf, Kristina M
title: Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials
date: 2020-04-15
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa444
sha: 597c87a48fb1765467ad833e4fcfbeee1f4cc346
doc_id: 937838
cord_uid: vqz6b7zy

Investigators are employing unprecedented innovation in the design of clinical trials to rapidly and rigorously assess potentially promising therapies for COVID-19; this is in stark contrast to the continued near universal regressive practice of exclusion of pregnant and breastfeeding women from these trials. The few trials which allow their inclusion focus on post-exposure prophylaxis or outpatient treatment of milder disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies. These restrictions were put in place despite experience with these drugs in pregnant women. In this Viewpoint, we call attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order to develop data-driven recommendations regarding the risks and benefits of therapies in this unique but not uncommon population.

A c c e p t e d M a n u s c r i p t VIEWPOINT The speed at which investigators have designed and initiated trials to evaluate potential COVID-19 therapeutics is truly astonishing. Less impressive is the continued exclusion of pregnant and lactating women from COVID-19 treatment trials. In this Viewpoint, we highlight the discrepancy between the innovative and adaptive ways in which investigators are evaluating COVID-19 therapeutics, in contrast to the continued regressive practice of excluding pregnant and lactating women from treatment trials.

While at this time there is no definitive evidence that pregnant women are at increased risk of infection or more severe outcomes, it is clear that pregnancy and the early postpartum periods present unique management challenges which require taking into account maternal, fetal, and neonatal risks and benefits [1] [2] [3] [4] [5] [6] . Exclusion of pregnant and breastfeeding women ensures these decisions will continue without the benefit of our highest levels of evidence.

Despite some experience using both remdesivir and hydroxychloroquine in pregnancy, there is near universal exclusion of pregnant women in COVID-19 clinical trials evaluating these potentially promising therapies. The few trials which allow their inclusion, focus on post-exposure prophylaxis or outpatient treatment of milder disease. This means the only options currently available to pregnant women with severe COVID-19 disease are limited to compassionate use of remdesivir, or off-label use of hydroxychloroquine or other therapies.

Remdesivir is a nucleotide analogue, initially developed for the treatment of Ebola Virus Disease (EVD), which shows promise for COVID-19. Notably, pregnant women were included in the Pamoja Tulinde Maisha (PALM, ["Together Save Lives" in the Kiswahili language]) randomized controlled trial of EVD therapeutics which compared ZMapp to MAb114, REGN-EB3, or remdesivir [7] . In the PALM trial, 6.1% hydroxychloroquine/azithromycin trial for outpatient treatment of milder disease. Recent data suggesting potential link with macrolides and fetal malformation will require additional counseling regarding the risk and benefits of azithromycin for prophylaxis for participants enrolling in early pregnancy [10] . These few studies, which allow inclusion of pregnant women, are in-line with recommendations from multiple Institutional Review Boards which support the policy of providing pregnant women with the same opportunities as non-pregnant women to participate in research, provided that participants are counseled on the known or possible reproductive or lactation risks from the study, and measures that will be taken to minimize them. Per our own institutional IRB guidance, research inclusive of pregnant women increases the likelihood that the knowledge gained can be extended judiciously to this population.

While an initial report of a handful of pregnant women with COVID-19 in the third trimester was somewhat reassuring in that pregnant women did not appear to be more susceptible to enhanced COVID-19 disease than non-pregnant adults [3] , other case series provide a more ominous view with higher rates of preterm labor and stillbirth than would be expected [1] , as well as the need for intensive care unit (ICU) admission for pregnant women [2] . In a case series of seven pregnant women hospitalized with COVID-19 in New York City, two women requiring ICU admission were asymptomatic upon initial presentation for indicated labor induction, were diagnosed after delivery, and received offlabel use of hydroxychloroquine [2] .

There are planned or ongoing observational studies and registries focused on COVID-19 in pregnancy, including in our own state of Washington, home to the first reported COVID-19 cases in the United States. While these studies will provide valuable information on maternal, pregnancy, and infant A c c e p t e d M a n u s c r i p t outcomes, including investigations on potential transmission, it will be difficult to interpret the clinical implications of treatment without a formal study design or comparator group.

There is widening recognition of the need to rapidly identify treatment options for pregnant and lactating women. The Task 

The authors report no conflicts of interest

Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy

COVID-19 in pregnancy: early lessons

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

Antibodies in Infants Born to Mothers With COVID-19 Pneumonia

Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China

Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of

Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis

Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: A systematic review and meta-analysis

Coalition to Advance Maternal Therapeutics

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t